Isavuconazonium sulfate is a Small Molecule owned by Basilea Pharmaceutica, and is involved in 42 clinical trials, of which 40 were completed, 1 is ongoing, and 1 is planned.

Isavuconazole blocks the synthesis of ergosterol, a key component of the fungal cell membrane, through the inhibition of cytochrome P450 (CYP) dependent enzyme lanosterol 14a-demethylase, which is responsible for the conversion of lanosterol to ergosterol in the fungal cell membrane. This results in an accumulation of methylated sterol precursors and a depletion of ergosterol within the cell membrane thus weakening the structure and function of the fungal cell membrane.

The revenue for Isavuconazonium sulfate is expected to reach a total of $162m through 2029. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Isavuconazonium sulfate NPV Report.

Isavuconazonium sulfate was originated by F. Hoffmann-La Roche and is currently owned by Basilea Pharmaceutica. Astellas Pharma is the other company associated in development or marketing of Isavuconazonium sulfate.

Isavuconazonium sulfate Overview

Isavuconazonium sulfate (Cresemba, BAL-4815, isavuconazole) is an azole anti-fungal agent. It is formulated as hard gelatin capsules for oral administration and injection powder for solution for intravenous administration. It is indicated for the treatment of invasive aspergillosis and invasive mucormycosis for whom amphotericin B is inappropriate.

It is under development for the treatment of fungal infections such as invasive aspergillosis, chronic lung aspergilosis, mucormycosis, and cryptococcosis. The drug candidate is also under development for Invasive aspergillosis and mucormycosis in pediatric patients. The drug candidate is also under development for the prevention of COVID-19-associated Pulmonary Aspergillosis. The drug candidate was also under development for the treatment of candidemia and other invasive Candida infections.

Basilea Pharmaceutica Overview

Basilea Pharmaceutica (Basilea) is a biopharmaceutical company that develops and markets antibiotics, antifungals and oncology drugs. The company products are for increasing resistance and non-response to present treatment options for various therapeutic areas such as cancer, bacterial infections and fungal infections. Basilea also conducts research in the areas of anti-infectives, cancer and bacterial or fungal strains. It discovers drugs with the help of various technologies such as genomics, assay development, cell biology and others. The company also operates in France, the UK, China, Germany, Spain, Switzerland, Italy and Denmark. Basilea is headquartered in Basel, Switzerland.

The company reported revenues of (Swiss Francs) CHF148.1 million for the fiscal year ended December 2021 (FY2021), an increase of 16.1% over FY2020. The operating profit of the company was CHF0.7 million in FY2021, compared to an operating loss of CHF8.5 million in FY2020. The net loss of the company was CHF6.8 million in FY2021, compared to a net loss of CHF14.7 million in FY2020.

Quick View – Isavuconazonium sulfate

Report Segments
  • Innovator (NME)
Drug Name
  • Isavuconazonium sulfate
Administration Pathway
  • Intravenous
  • Oral
Therapeutic Areas
  • Infectious Disease
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.